Starcoin Group Seeks Review of HKEX Ruling on Insufficient Operations

Innovative Pharmaceutical Biotech ( (HK:0399) ) has shared an update.

Starcoin Group Limited has disclosed that the Hong Kong stock exchange has determined the company failed to maintain a sufficient level of operations as required under listing rules, a finding previously upheld by the Listing Committee. The group, whose shares trade in Hong Kong, faces questions about its ongoing compliance and the sustainability of its current business scale.

In response, the company has formally requested that the Listing Review Committee re-examine the Listing Committee’s decision made under Rule 13.24. Starcoin has cautioned shareholders and potential investors that the outcome of this review is uncertain and urged them to exercise care in trading its securities while awaiting further announcements on the process.

The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.06 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.

More about Innovative Pharmaceutical Biotech

Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company incorporated in the Cayman Islands and continued in Bermuda with limited liability. The group is listed on the Main Board of the Stock Exchange of Hong Kong under stock code 399, and its operations have recently come under scrutiny for the sufficiency of its business activities under local listing rules.

Average Trading Volume: 19,344,327

Technical Sentiment Signal: Sell

Current Market Cap: HK$130.7M

For an in-depth examination of 0399 stock, go to TipRanks’ Overview page.